Compound profile
Gonadorelin
Limited human dataAlso known as: GnRH · Gonadotropin-releasing hormone · Factrel · Lutrepulse
The synthetic form of the body's own gonadotropin-releasing hormone, historically FDA-approved for pituitary function testing and pulsatile ovulation induction. Now widely discussed off-label alongside testosterone replacement therapy to help preserve natural testicular function and fertility.
Overview
Gonadorelin is a synthetic version of GnRH, the decapeptide the hypothalamus releases in pulses to drive the entire reproductive hormone cascade, stimulating the pituitary to release LH and FSH, which in turn signal the testes or ovaries. It has a genuine, decades-old regulatory history: the FDA approved gonadorelin products including Factrel and Lutrepulse for diagnostic pituitary function testing and for inducing ovulation in women with hypothalamic amenorrhea, using pump-delivered pulsatile dosing that mimics the body's natural release pattern.
Those original branded products have since been discontinued in the US market for business reasons, though gonadorelin remains available and clinically used in other contexts, including veterinary medicine and compounding pharmacies. Its diagnostic use, the GnRH stimulation test, has been substantially replaced in many settings by longer-acting GnRH agonists like triptorelin, which give a more sustained and easily measured response.
The use case driving most current interest is different from either of those approved indications: preserving fertility and testicular size in men on testosterone replacement therapy, where exogenous testosterone otherwise suppresses the body's own LH and FSH signaling. This application relies on gonadorelin's basic mechanism but has not itself been the subject of the kind of large randomized trials that supported the original approvals.
Mechanism (plain language)
Binds GnRH receptors on pituitary gonadotrope cells, stimulating pulsatile release of LH and FSH, which in turn drive testicular or ovarian hormone production; when given in the body's natural pulsatile pattern it stimulates the axis, while continuous, non-pulsatile exposure eventually desensitizes it.
How it works
Gonadorelin activates GnRH receptors on gonadotrope cells in the anterior pituitary, prompting them to release LH and FSH into the bloodstream. In men, LH signals the testes' Leydig cells to produce testosterone and maintain testicular volume, while FSH supports sperm production; in women, the same two hormones drive follicular development and ovulation. Because the hypothalamus normally releases GnRH in pulses roughly every 60 to 120 minutes, replicating that pulsatile pattern, historically done with a wearable infusion pump for ovulation induction, is what allows gonadorelin to stimulate the axis rather than suppress it.
This pulsatility requirement is also gonadorelin's most important pharmacological quirk: continuous, non-pulsatile exposure to GnRH or its longer-acting analogs eventually desensitizes and downregulates the pituitary's GnRH receptors, shutting the axis down instead of stimulating it, which is the exact mechanism GnRH agonist drugs exploit therapeutically for conditions like precocious puberty or prostate cancer. In the TRT-adjunct context, gonadorelin is typically dosed as small, frequent injections intended to intermittently stimulate LH and FSH release and keep the testes responsive, counteracting the suppression that exogenous testosterone otherwise causes.
What research suggests
Older clinical trials robustly support pulsatile gonadorelin for inducing ovulation in hypothalamic amenorrhea, with high reported ovulation and pregnancy rates. Its use for preserving fertility and testicular function in men on testosterone therapy is mechanistically sound but has not been validated in large controlled trials.
Reported benefits
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
High ovulation rates in hypothalamic amenorrhea
Clinical studies of pulsatile gonadorelin reported ovulation in over 90 percent of treatment cycles in women with hypothalamic amenorrhea, historically considered a first-line treatment for this cause of infertility.
Established diagnostic use
The GnRH stimulation test using gonadorelin has long been used to distinguish different causes of delayed or precocious puberty and to assess pituitary-gonadal axis function.
Mechanistic basis for TRT-adjunct use
Because gonadorelin directly stimulates the same LH/FSH pathway that exogenous testosterone suppresses, it is used off-label to keep the testes responsive and preserve size and fertility potential in men on testosterone replacement, an application grounded in established endocrinology though not itself extensively trial-tested.
Uncertainties & risks
Its strongest evidence base is decades old and specific to the discontinued branded products used for ovulation induction and diagnostic testing. The popular current use case, fertility preservation during TRT, lacks large randomized trials and relies on extrapolation from gonadorelin's known mechanism rather than direct outcome data for that specific application.
Gonadorelin's core pharmacology, pulsatile dosing stimulates the reproductive axis while continuous exposure suppresses it, is well established and is the same principle exploited by GnRH agonist drugs used for the opposite purpose. Because the original approved products are discontinued, gonadorelin used today, whether for TRT-adjunct purposes or compounded ovulation induction, generally comes from compounding pharmacies rather than an FDA-regulated manufacturing process, which affects consistency and purity assurance. Dosing frequency matters mechanistically: infrequent or irregular dosing intended to mimic a pulsatile pattern is a different pharmacological exposure than the older pump-delivered protocols actually studied, and how closely common off-label TRT-adjunct regimens replicate that pattern varies by protocol.
Side effects
Commonly reported
- Headache: Reported in ovulation-induction trials
- Nausea: Reported in a subset of patients
- Injection or infusion-site reactions: Reported with both bolus and pump-delivered dosing
- Multiple pregnancy risk: A known risk of ovulation-induction therapy generally, relevant to its fertility indication
Reported in the cited literature, not a complete list, and not medical advice. Individual responses vary; consult a qualified professional.
STACKD study summaries
Start with our in-house roundups, plain-language synthesis of the research, with primary sources cited at the bottom of each.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.